Publications by authors named "E Quintana-Gallego"
Background: Cystic fibrosis (CF) patients are prone to recurrent multi-drug-resistant (MDR) bacterial lung infections. Under this scenario, phage therapy has been proposed as a promising tool. However, the limited number of reported cases hampers the understanding of clinical outcomes.
View Article and Find Full Text PDFArticle Synopsis
- There is significant confusion regarding the correct dosage of inhaled medications, prompting a review of inhalation therapy devices.
- A systematic search identified 90 unique inhalation products, noting variations in long-acting bronchodilators and inhaled corticosteroids, with different marketing practices for dosages.
- The findings indicate that each inhaled drug may have multiple dosage forms, emphasizing the need for clinicians to be cautious when prescribing these medications.
Introduction: Elexacaftor/tezacaftor/ivacaftor (ETI) was used through the early access programme in Spain from December 2019 in cystic fibrosis (CF) patients with homozygous or heterozygous F508del mutation with advanced lung disease.
Methodology: Multicentre, ambispective, observational, study in which 114 patients in follow-up in 16 national CF units were recruited. Clinical data, functional tests, nutritional parameters, quality of life questionnaires, microbiological isolates, number of exacerbations, antibiotic treatments and side effects were collected.